221 related articles for article (PubMed ID: 38546391)
21. Association of PD-1 and PD-L1 Genetic Polymorphyisms with Type 1 Diabetes Susceptibility.
Qian C; Guo H; Chen X; Shi A; Li S; Wang X; Pan J; Fang C
J Diabetes Res; 2018; 2018():1614683. PubMed ID: 30534571
[TBL] [Abstract][Full Text] [Related]
22. Polymorphisms of the PD-L1 gene 3'-untranslated region are associated with the expression of PD-L1 in non-small cell lung cancer.
Ohhara Y; Tomaru U; Kinoshita I; Hatanaka KC; Noguchi T; Hatanaka Y; Amono T; Matsuno Y; Dosaka-Akita H
Genes Chromosomes Cancer; 2024 Jan; 63(1):e23216. PubMed ID: 38169142
[TBL] [Abstract][Full Text] [Related]
23. Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients.
Nomizo T; Ozasa H; Tsuji T; Funazo T; Yasuda Y; Yoshida H; Yagi Y; Sakamori Y; Nagai H; Hirai T; Kim YH
Sci Rep; 2017 Mar; 7():45124. PubMed ID: 28332580
[TBL] [Abstract][Full Text] [Related]
24. Association of PD-1 and PDL-1 gene polymorphisms with colorectal cancer risk and prognosis.
Cevik M; Namal E; Iner-Koksal U; Dinc-Sener N; Karaalp A; Ciftci C; Susleyici B
Mol Biol Rep; 2022 Mar; 49(3):1827-1836. PubMed ID: 35076848
[TBL] [Abstract][Full Text] [Related]
25. The role of genetic polymorphism within PD-L1 gene in cancer. Review.
Kula A; Dawidowicz M; Kiczmer P; Prawdzic Seńkowska A; Świętochowska E
Exp Mol Pathol; 2020 Oct; 116():104494. PubMed ID: 32679050
[TBL] [Abstract][Full Text] [Related]
26. PD-L1 polymorphism can predict clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel-cisplatin chemotherapy.
Lee SY; Jung DK; Choi JE; Jin CC; Hong MJ; Do SK; Kang HG; Lee WK; Seok Y; Lee EB; Jeong JY; Shin KM; Yoo SS; Lee J; Cha SI; Kim CH; Park JY
Sci Rep; 2016 May; 6():25952. PubMed ID: 27181838
[TBL] [Abstract][Full Text] [Related]
27. Counter-regulation of rejection activity against human liver grafts by donor PD-L1 and recipient PD-1 interaction.
Shi XL; Mancham S; Hansen BE; de Knegt RJ; de Jonge J; van der Laan LJ; Rivadeneira F; Metselaar HJ; Kwekkeboom J
J Hepatol; 2016 Jun; 64(6):1274-82. PubMed ID: 26941095
[TBL] [Abstract][Full Text] [Related]
28. Association of a
Venugopal G; O'Regan NL; Babu S; Schumann RR; Srikantam A; Merle R; Hartmann S; Steinfelder S
Am J Trop Med Hyg; 2019 Feb; 100(2):344-350. PubMed ID: 30594267
[TBL] [Abstract][Full Text] [Related]
29. Association between single nucleotide polymorphism of PD-L1 gene and non-small cell lung cancer susceptibility in a Chinese population.
Chen YB; Mu CY; Chen C; Huang JA
Asia Pac J Clin Oncol; 2014 Jun; 10(2):e1-6. PubMed ID: 23167931
[TBL] [Abstract][Full Text] [Related]
30. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
31. [Influence of genetic variation of programmed death-ligand 1 (PD-L1) on the prognosis of patients with non-small cell lung cancer who received platinum-based adjuvant chemotherapy].
Zhang GW; Cheng RR; Zhang FR; Li P; Chu HY; Song XJ; Zhang GJ
Zhonghua Yi Xue Za Zhi; 2020 Sep; 100(34):2682-2688. PubMed ID: 32921017
[No Abstract] [Full Text] [Related]
32. Genetic variants of programmed cell death 1 are associated with HBV infection and liver disease progression.
Hoan NX; Huyen PTM; Binh MT; Trung NT; Giang DP; Linh BT; Dung DTN; Pallerla SR; Kremsner PG; Velavan TP; Bang MH; Song LH
Sci Rep; 2021 Apr; 11(1):7772. PubMed ID: 33833369
[TBL] [Abstract][Full Text] [Related]
33. The association of PD-L1 gene polymorphisms with non-small-cell lung cancer susceptibility and clinical outcomes in a Chinese population.
Zhao X; Peng Y; Li X; Zhang S; Peng Y; Shan J; Li M; Dai N; Feng Y; Xu C; Wang D
Int J Clin Exp Pathol; 2020; 13(8):2130-2136. PubMed ID: 32922610
[TBL] [Abstract][Full Text] [Related]
34. PD-1 gene rs10204525 and rs7421861 polymorphisms are associated with increased risk and clinical features of esophageal cancer in a Chinese Han population.
Zang B; Chen C; Zhao JQ
Aging (Albany NY); 2020 Feb; 12(4):3771-3790. PubMed ID: 32084010
[No Abstract] [Full Text] [Related]
35. PD-L1 gene polymorphism and high level of plasma soluble PD-L1 protein may be associated with non-small cell lung cancer.
Cheng S; Zheng J; Zhu J; Xie C; Zhang X; Han X; Song B; Ma Y; Liu J
Int J Biol Markers; 2015 Nov; 30(4):e364-8. PubMed ID: 26349666
[TBL] [Abstract][Full Text] [Related]
36. Association of PD-1, PD-L1, and CTLA-4 Gene Expression and Clinicopathologic Characteristics in Patients With Non-Small-Cell Lung Cancer.
Lafuente-Sanchis A; Zúñiga Á; Estors M; Martínez-Hernández NJ; Cremades A; Cuenca M; Galbis JM
Clin Lung Cancer; 2017 Mar; 18(2):e109-e116. PubMed ID: 27816393
[TBL] [Abstract][Full Text] [Related]
37. [Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations].
Jiang L; Lin Z; Li N; Jiang J; Lu C; Du S; Zhang J; Wang Y; Chen J; Gong P
Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):623-631. PubMed ID: 34455737
[TBL] [Abstract][Full Text] [Related]
38. Potential role of immune cell genetic variants associated with tumor microenvironment response in laryngeal squamous cell carcinoma (LSCC) in terms of clinicopathological features.
Horozoglu C; Sonmez D; Demirkol S; Hakan MT; Kaleler I; Hepokur C; Verim A; Yaylim I
Pathol Res Pract; 2021 Dec; 228():153665. PubMed ID: 34717150
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma.
Gao Y; Li S; Xu D; Chen S; Cai Y; Jiang W; Zhang X; Sun J; Wang K; Chang B; Wang F; Hong M
Chin J Cancer; 2017 Jul; 36(1):61. PubMed ID: 28754154
[TBL] [Abstract][Full Text] [Related]
40. PD-L1
Li Q; Zhou ZW; Lu J; Luo H; Wang SN; Peng Y; Deng MS; Song GB; Wang JM; Wei X; Wang D; Westover KD; Xu CX
Mol Ther; 2022 Feb; 30(2):621-631. PubMed ID: 34547468
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
